Cevostamab (BFCR4350A), a bispecific antibody developed by Roche, induces durable and deep responses in heavily pre-treated patients with relapsed or refractory multiple myeloma, according to early data from a Phase 1 trial. Preliminary data from the trial, called GO39775 (NCT03275103), also showed cevostamab had a manageable safety and toxicity profile when given in a single step-up dosing manner. “Our data reflect our ongoing commitment to following the science and improving the lives of patients with…
You must be logged in to read/download the full post.
The post Roche’s Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients appeared first on BioNewsFeeds.